Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3D Medicines Approved to Launch Anti-PD-L1 in China

publication date: Nov 26, 2021

3D Medicines reported that China's NMPA approved the launch of its anti-PD-L1 therapy, the first subcutaneously administered anti-PD-L1 approved anywhere in the world. Envafolimab, a novel single-domain antibody against PD-L1, is approved as a second line therapy for MSI-H/dMMR cancer in patients with advanced solid tumors. Alphamab Oncology originally discovered the drug, and 3D Medicines became its partner, with both companies responsible for clinical development. Tracon Pharma shares US rights to envafolimab with the two China biopharmas while Simcere will commercialize envafolimab in China. More details...

Stock Symbols: (HK: 9966) (NSDQ: TCON)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022